Journal club: PIONEER 6 as a safety trial

PIONEER 6 has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.

The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.

On PIONEER 6: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

Where I part company with post #9, and it is a narrow parting.

PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to establish benefit, though point estimates favoured the drug.

The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.

The claim is narrower than it sounds, and deliberately so.